Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1977 1
1980 3
1981 2
1982 2
1983 2
1984 2
1985 3
1986 1
1987 5
1988 2
1989 1
1990 3
1991 8
1992 4
1993 3
1994 7
1995 12
1996 17
1997 8
1998 19
1999 31
2000 45
2001 61
2002 62
2003 44
2004 29
2005 51
2006 38
2007 17
2008 20
2009 14
2010 37
2011 28
2012 25
2013 36
2014 43
2015 33
2016 27
2017 22
2018 30
2019 29
2020 27
2021 24
2022 29
2023 28
2024 25
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

879 results

Results by year

Filters applied: . Clear all
Page 1
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.
Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers P, Hernandez-Ilizaliturri F, Izutsu K, Morschhauser F, Lunning M, Maloney DG, Crotta A, Montheard S, Previtali A, Stepan L, Ogasawara K, Mack T, Abramson JS; TRANSFORM Investigators. Kamdar M, et al. Among authors: maloney dg. Lancet. 2022 Jun 18;399(10343):2294-2308. doi: 10.1016/S0140-6736(22)00662-6. Lancet. 2022. PMID: 35717989 Clinical Trial.
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.
Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G, Munshi PN, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Yakoub-Agha I, Oluwole OO, Fung HCH, Rosenblatt J, Rossi JM, Goyal L, Plaks V, Yang Y, Vezan R, Avanzi MP, Neelapu SS. Jacobson CA, et al. Among authors: maloney dg. Lancet Oncol. 2022 Jan;23(1):91-103. doi: 10.1016/S1470-2045(21)00591-X. Epub 2021 Dec 8. Lancet Oncol. 2022. PMID: 34895487 Clinical Trial.
Psychotherapies for eating disorders: findings from a rapid review.
Russell H, Aouad P, Le A, Marks P, Maloney D; National Eating Disorder Research Consortium; Touyz S, Maguire S. Russell H, et al. Among authors: maloney d. J Eat Disord. 2023 Oct 4;11(1):175. doi: 10.1186/s40337-023-00886-w. J Eat Disord. 2023. PMID: 37794513 Free PMC article. Review.
Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade.
Srivastava S, Furlan SN, Jaeger-Ruckstuhl CA, Sarvothama M, Berger C, Smythe KS, Garrison SM, Specht JM, Lee SM, Amezquita RA, Voillet V, Muhunthan V, Yechan-Gunja S, Pillai SPS, Rader C, Houghton AM, Pierce RH, Gottardo R, Maloney DG, Riddell SR. Srivastava S, et al. Among authors: maloney dg. Cancer Cell. 2021 Feb 8;39(2):193-208.e10. doi: 10.1016/j.ccell.2020.11.005. Epub 2020 Dec 24. Cancer Cell. 2021. PMID: 33357452 Free PMC article.
Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study.
Siddiqi T, Maloney DG, Kenderian SS, Brander DM, Dorritie K, Soumerai J, Riedell PA, Shah NN, Nath R, Fakhri B, Stephens DM, Ma S, Feldman T, Solomon SR, Schuster SJ, Perna SK, Tuazon SA, Ou SS, Papp E, Peiser L, Chen Y, Wierda WG. Siddiqi T, et al. Among authors: maloney dg. Lancet. 2023 Aug 19;402(10402):641-654. doi: 10.1016/S0140-6736(23)01052-8. Epub 2023 Jun 6. Lancet. 2023. PMID: 37295445 Clinical Trial.
Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells.
Gust J, Hay KA, Hanafi LA, Li D, Myerson D, Gonzalez-Cuyar LF, Yeung C, Liles WC, Wurfel M, Lopez JA, Chen J, Chung D, Harju-Baker S, Özpolat T, Fink KR, Riddell SR, Maloney DG, Turtle CJ. Gust J, et al. Among authors: maloney dg. Cancer Discov. 2017 Dec;7(12):1404-1419. doi: 10.1158/2159-8290.CD-17-0698. Epub 2017 Oct 12. Cancer Discov. 2017. PMID: 29025771 Free PMC article.
Rituximab resistance.
Rezvani AR, Maloney DG. Rezvani AR, et al. Among authors: maloney dg. Best Pract Res Clin Haematol. 2011 Jun;24(2):203-16. doi: 10.1016/j.beha.2011.02.009. Epub 2011 Apr 13. Best Pract Res Clin Haematol. 2011. PMID: 21658619 Free PMC article. Review.
Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL.
Liang EC, Albittar A, Huang JJ, Hirayama AV, Kimble EL, Portuguese AJ, Chapuis A, Shadman M, Till BG, Cassaday RD, Milano F, Kiem HP, Riddell SR, Turtle CJ, Maloney DG, Gauthier J. Liang EC, et al. Among authors: maloney dg. Blood Adv. 2023 Nov 28;7(22):6990-7005. doi: 10.1182/bloodadvances.2023011399. Blood Adv. 2023. PMID: 37774014 Free PMC article. Clinical Trial.
879 results